BlackRock
FHTX icon

BlackRock’s Foghorn Therapeutics FHTX Stock Holding History

BlackRock’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.8M Buy
2,626,832
+261,966
+11% +$1.16M ﹤0.01% 3540
2026
Q1 		$11.3M Buy
2,364,866
+14,996
+0.6% +$82.3K ﹤0.01% 3416
2025
Q4 		$12.7M Buy
2,349,870
+89,922
+4% +$408K ﹤0.01% 3353
2025
Q3 		$11.1M Buy
2,259,948
+30,815
+1% +$163K ﹤0.01% 3409
2025
Q2 		$10.5M Buy
2,229,133
+233,232
+12% +$975K ﹤0.01% 3392
2025
Q1 		$7.29M Sell
1,995,901
-33,307
-2% -$152K ﹤0.01% 3476
2024
Q4 		$9.58M Buy
2,029,208
+217,906
+12% +$1.59M ﹤0.01% 3457
2024
Q3 		$16.9M Buy
1,811,302
+265,233
+17% +$1.92M ﹤0.01% 3148
2024
Q2 		$8.89M Buy
1,546,069
+230,698
+18% +$1.37M ﹤0.01% 3440
2024
Q1 		$8.83M Buy
1,315,371
+9,503
+0.7% +$52.8K ﹤0.01% 3408
2023
Q4 		$8.42M Sell
1,305,868
-85,890
-6% -$371K ﹤0.01% 3481
2023
Q3 		$6.96M Sell
1,391,758
-63,681
-4% -$491K ﹤0.01% 3520
2023
Q2 		$10.2M Buy
1,455,439
+212,919
+17% +$1.49M ﹤0.01% 3408
2023
Q1 		$7.7M Sell
1,242,520
-7,508
-0.6% -$49.1K ﹤0.01% 3455
2022
Q4 		$7.98M Buy
1,250,028
+192,850
+18% +$1.45M ﹤0.01% 3497
2022
Q3 		$9.07M Sell
1,057,178
-26,496
-2% -$341K ﹤0.01% 3477
2022
Q2 		$14.7M Sell
1,083,674
-32,960
-3% -$425K ﹤0.01% 3266
2022
Q1 		$17M Sell
1,116,634
-31,339
-3% -$430K ﹤0.01% 3277
2021
Q4 		$26.3M Buy
1,147,973
+28,288
+3% +$407K ﹤0.01% 3115
2021
Q3 		$15.6M Buy
1,119,685
+25,825
+2% +$286K ﹤0.01% 3443
2021
Q2 		$11.7M Buy
1,093,860
+661,735
+153% +$7.21M ﹤0.01% 3590
2021
Q1 		$5.7M Sell
432,125
-240,079
-36% -$3.93M ﹤0.01% 3880
2020
Q4 		$13.6M Buy
+672,204
New +$12.9M ﹤0.01% 3212

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock's FHTX Position: Q2 2026 in Review

BlackRock increased its Foghorn Therapeutics (FHTX) stake by 11% in Q2 2026, buying an estimated $1.16M and bringing the position to 2,626,832 shares worth $12.8M. The position accounts for ﹤0.01% of the portfolio, ranked #3540.

BlackRock first reported a position in FHTX in Q4 2020 and has held it in 23 quarters since. The position peaked at $26.3M in Q4 2021. 103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • BlackRock held 2,626,832 shares of Foghorn Therapeutics worth $12.8M as of Q2 2026.
  • BlackRock bought 261,966 Foghorn Therapeutics shares in Q2 2026, an estimated $1.16M.
  • Foghorn Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3540 holding.
  • BlackRock first reported a position in Foghorn Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • BlackRock's Foghorn Therapeutics position peaked at $26.3M in Q4 2021.
  • 103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.